ABSTRACT
A radioimmunological analysis of the changes in concentration of tumour markers CA 19-9, REA, beta 2-microglobulin, trypsin and C-peptide was carried out in 53 patients with pancreatic cancer and in 14 patients with cancer of the major duodenal papilla before and 7-10 days after the treatment. A control group was comprised of 116 volunteers. The levels of the tumour markers decreased after the combined use of remote radiotherapy and pancreaticoduodenal resection (PDR). After creation of cholecysto-enteroanastomosis and performance of radiotherapy they remained without changes. Exocrine pancreatic function after remote radiotherapy, especially in combination with PDR, was sharply suppressed.
Subject(s)
Ampulla of Vater , Biomarkers, Tumor/analysis , C-Peptide/analysis , Common Bile Duct Neoplasms/metabolism , Pancreatic Neoplasms/metabolism , Trypsin/analysis , CA-19-9 Antigen/analysis , Combined Modality Therapy , Common Bile Duct Neoplasms/therapy , Humans , Lewis X Antigen/analysis , Pancreatic Neoplasms/therapy , Prohibitins , Radioimmunoassay , Surgical Procedures, Operative/methods , Time Factors , Treatment Outcome , beta 2-Microglobulin/analysisABSTRACT
Radioimmunological examination of beta 2-microglobulin in the blood serum of 525 patients revealed that increased protein levels were observed in patients with malignant tumours of the pancreas, duodenal papilla, ovaries, soft tissues, lymphomas. In benign diseases (pancreatitis, ovarian cysts) the beta 2-microglobulin concentration did not significantly exceed the discrimination value. Due to the low sensitivity and specificity this protein has dubious significance as a tumour marker. It is suggested that in some cases of malignant tumours changes of the beta 2-microglobulin level may be related to hepatorenal insufficiency, spread of the disease. These data may provide supplementary information on the prognosis and evolution of the tumour process after combined treatment.
Subject(s)
Neoplasms/blood , beta 2-Microglobulin/analysis , Adult , Child , Humans , Neoplasms/diagnosis , Prognosis , RadioimmunoassayABSTRACT
The content of fibrin fibrinogen splitting products (FSP), radioimmune trypsin, C-peptide and carbohydrate antigen (CA) 19-9 in the blood of 82 patients with acute pancreatitis (edematous and hemorrhagic), and chronic recurrent pancreatitis at the stage of exacerbation, 42 patients with chronic pancreatitis, 34 patients with cancer of the pancreas (stages III-IV) and 22 healthy persons were studied. Results indicate a high diagnostic value of determination FSP, trypsin and C-peptide in patients with acute pancreatitis and chronic recurring pancreatitis at the stage of exacerbation, trypsin and C-peptide in patients with chronic pancreatitis associated with severe exocrine insufficiency of the pancreas, KA 19-9 in patients with cancer of the pancreas.
Subject(s)
Pancreatic Neoplasms/diagnosis , Pancreatitis/diagnosis , Acute Disease , Antigens, Tumor-Associated, Carbohydrate/analysis , C-Peptide/blood , Chronic Disease , Diagnosis, Differential , Fibrin Fibrinogen Degradation Products/analysis , Humans , Recurrence , Trypsin/bloodABSTRACT
The CA 19-9 antigen content was studied in 163 patients with pancreatic diseases by radioimmunologic method with the use of commercial test-kits ("Sorin", France). Pancreatitis was diagnosed in 67 patients, pancreatic cancer--in 23, cancer of the major duodenal papilla (MDP)--in 14, malignant neoplasms of the stomach, colon and rectum, liver--in 58. All the results were verified by morphologic studies. The control group included 22 donors. In patients with pancreatic cancer, the considerable increase in the CA 19-9 level was noted when compared with antigen content in the norm and in the other patients examined. The indices of CA 19-9 in pancreatitis don't differ from the normal ones. In MDP cancer and malignant tumours of other location with tumour invasion into the pancreas, the serum CA 19-9 level was increased.